Vertex Pharmaceuticals

Direction: Raised

Revenue: “htm EX-99.1 Document Vertex Reports Second Quarter 2025 Financial Results Total revenue of $2.96 billion, a 12% increase compared to Q2 2024 reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion Continued strong execution of CASGEVY , ALYFTREK and JOURNAVX launches Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD David Altshuler, M.”

Revenue: “2 Full Year 2025 Financial Guidance Vertex today reiterated its full year 2025 financial guidance, including revenue guidance of $11.85 billion to $12 billion, which assumes continued growth in CF, including the global launch of ALYFTREK continued uptake of CASGEVY in multiple regions and early contributions from the U.”

Company outlook: “Vertex also reiterated its guidance for both combined GAAP and non-GAAP R D, AIPR D, and SG A expenses, which includes expectations for continued investment in multiple mid- and late-stage clinical development programs and commercial capabilities, and AIPR D expenses of approximately $100 million.”

Company outlook: “In addition, Vertex reiterated non-GAAP effective tax rate guidance of 20.5-21.5%.”

Revenue: “Vertex s financial guidance is summarized below Current FY 2025 Previous FY 2025 Total revenue Unchanged $11.85 to $12.0 billion Combined GAAP R D, AIPR D and SG A expenses * Unchanged $5.55 to $5.7 billion Combined non-GAAP R D, AIPR D and SG A expenses * Unchanged $4.9 to $5.0 billion Non-GAAP effective tax rate Unchanged 20.5% to 21.5% *The difference between the combined GAAP R D, AIPR D and SG A expenses and the combined non-GAAP R D, AIPR D and SG A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense.”

Company outlook: “Kewalramani's statements in this press release, the information provided regarding future financial performance and operations, the section captioned Full Year 2025 Financial Guidance and statements regarding (i) expectations for Vertex s continued growth in CF, including by increasing the number of CF patients taking its medicines through new approvals and reimbursements, treatment of younger patients, increased survival, and expansion into additional geographies, (ii) expectations regarding access to ALYFTREK in Ireland and other E.”

Revenue — Raised (“increase”)
“htm EX-99.1 Document Vertex Reports Second Quarter 2025 Financial Results Total revenue of $2.96 billion, a 12% increase compared to Q2 2024 reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion Continued strong execution of CASGEVY , ALYFTREK and JOURNAVX launches Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD David Altshuler, M.”

Company outlook — Reiterated (“reiterated”)
“, SVP of Global Research, to assume role of CSO effective February 1, 2026 BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 financial guidance.”

Revenue — Reiterated (“reiterated”)
“2 Full Year 2025 Financial Guidance Vertex today reiterated its full year 2025 financial guidance, including revenue guidance of $11.85 billion to $12 billion, which assumes continued growth in CF, including the global launch of ALYFTREK continued uptake of CASGEVY in multiple regions and early contributions from the U.”

Company outlook — Reiterated (“reiterated”)
“Vertex also reiterated its guidance for both combined GAAP and non-GAAP R D, AIPR D, and SG A expenses, which includes expectations for continued investment in multiple mid- and late-stage clinical development programs and commercial capabilities, and AIPR D expenses of approximately $100 million.”

Company outlook — Reiterated (“reiterated”)
“In addition, Vertex reiterated non-GAAP effective tax rate guidance of 20.5-21.5%.”

Revenue — Reiterated (“Unchanged”)
“Vertex s financial guidance is summarized below Current FY 2025 Previous FY 2025 Total revenue Unchanged $11.85 to $12.0 billion Combined GAAP R D, AIPR D and SG A expenses * Unchanged $5.55 to $5.7 billion Combined non-GAAP R D, AIPR D and SG A expenses * Unchanged $4.9 to $5.0 billion Non-GAAP effective tax rate Unchanged 20.5% to 21.5% *The difference between the combined GAAP R D, AIPR D and SG A expenses and the combined non-GAAP R D, AIPR D and SG A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense.”

Company outlook — Raised (“increases”)
“In particular, non-GAAP financial results and guidance exclude from Vertex's pre-tax income (loss) (i) stock-based compensation expense, (ii) intangible asset amortization expense, (iii) gains or losses related to the fair value of the company's strategic investments, (iv) increases or decreases in the fair value of contingent consideration, (v) acquisition-related costs, (vi) an intangible asset impairment charge, and (vii) other adjustments.”

Company outlook — Raised (“increasing”)
“Kewalramani's statements in this press release, the information provided regarding future financial performance and operations, the section captioned Full Year 2025 Financial Guidance and statements regarding (i) expectations for Vertex s continued growth in CF, including by increasing the number of CF patients taking its medicines through new approvals and reimbursements, treatment of younger patients, increased survival, and expansion into additional geographies, (ii) expectations regarding access to ALYFTREK in Ireland and other E.”

Classified from the release's primary full-year outlook statement.